Self-Administered Etripamil Safe, Effective for Paroxysmal Supraventricular Tachycardia

FRIDAY, Sept. 29, 2023 (HealthDay News) -- Investigational etripamil nasal spray is well tolerated for self-treating recurrent episodes of paroxysmal supraventricular tachycardia (PSVT) without medical supervision, according to a study published online Sept. 27 in the Journal of the American Heart Association.
James E. Ip, M.D., from Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York City, and colleagues conducted an open-label extension of the phase 3 NODE-301 to assess the safety and efficacy of the L‐type calcium channel blocker etripamil. The analysis included 105 patients who were monitored via a self-applied cardiac monitoring system for five hours after etripamil self-administration for PSVT.
The researchers found that during a median 232 days of follow-up, the probability of conversion within 30 minutes of etripamil was 60.2 percent (median time to conversion, 15.5 minutes) among 188 PSVT episodes (92 patients) positively adjudicated as atrioventricular nodal-dependent by independent electrocardiogram analysis. Forty patients self-treated two PSVT episodes, and among these participants, three-quarters had a significantly consistent response by 30 minutes, nine did not convert on either episode, and 21 converted on both episodes. Treatment-emergent adverse events occurred in 42.9 percent of patients, which were generally transient and mild-to-moderate (e.g., nasal congestion [14.3 percent], nasal discomfort [14.3 percent], or rhinorrhea [12.4 percent]). Within 24 hours of etripamil self-administration, no serious cardiac safety events were seen.
"This is a potential new and exciting option for patients to safely self-treat their rapid heartbeat without direct medical supervision to avoid emergency room visits and medical interventions," Ip said in a statement.
Several authors disclosed ties to pharmaceutical companies, including Milestone Pharmaceuticals, which manufactures etripamil and funded the study.
Related Posts
Social Isolation, Loneliness Up Risk of New CVD in Older Women
THURSDAY, Feb. 3, 2022 (HealthDay News) -- Social isolation and loneliness are...
Leading U.S. Pediatricians’ Group Issues Guidelines to Prevent Patient Abuse
MONDAY, Aug. 29, 2022 (HealthDay News) -- Recent years have seen several...
La FDA advierte de unos casos raros de ciertos tipos de cáncer vinculados con los implantes de senos
VIERNES, 9 de septiembre de 2022 (HealthDay News) -- La Administración de...
Breakthrough CAR-T Cancer Treatments Are Boosting Patients’ Quality of Life
WEDNESDAY, April 5, 2023 (HealthDay News) -- A therapy that bolsters the immune...
